Drug Trial Radar · NCT04128163
Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk
Last checked: Nov 19, 2026Latest source record: Nov 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
440
Planned (sponsor's estimate)
Start
Jun 5, 2019
Primary completion
Aug 31, 2021
Study completion Dec 1, 2021
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III trial to compare the efficacy and safety of QL1206 and placebo in postmenopausal women with osteoporosis at high risk of fracture
Conditions
- Postmenopausal Osteoporosis
Interventions
QL1206Drug
subcutaneous injection of 60 mg(60mg:1ml), Q6M, twice for one year. Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU
PlacebosDrug
subcutaneous injection of(1ml), Q6M, twice for one year. Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine from Baseline up to 12 monthsTime frame: Baseline and Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai sixth people's hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.